Stifel Downgrades Immunovant to Hold, Lowers Price Target to $9

Stifel analyst Derek Archila downgrades Immunovant (NASDAQ:IMVT) from Buy to Hold and lowers the price target from $28 to $9.

Stifel analyst Derek Archila downgrades Immunovant (NASDAQ:IMVT) from Buy to Hold and lowers the price target from $28 to $9.

Total
0
Shares
Related Posts